Table 1 Overview of pembrolizumab immunogenicity findings

Stratified by treatment

All treatments

2 mg/kg Q3W

10 mg/kg Q3W/Q2W

200 mg Q3W

 Assessable patients^a

3655

667

2007

981

 Inconclusive patients^b

1655

125

1462

68

 Evaluable patients^c

2000

542

545

913

  Negative^d

1943 (97.2%)

527 (97.2%)

529 (97.8%)

887 (97.2%)

  Non–treatment-emergent positive^d

21 (1.1%)

7 (1.3%)

4 (0.7%)

10 (1.1%)

   Neutralizing negative

19 (1.0%)

5 (0.9%)

4 (0.7%)

10 (1.1%)

   Neutralizing positive

2 (0.1%)

2 (0.4%)

  Treatment-emergent positive^d

36 (1.8%)

8 (1.5%)

12 (2.2%)

16 (1.8%)

   Neutralizing negative

27 (1.4%)

6 (1.1%)

11 (2.0%)

10 (1.1%)

   Neutralizing positive

9 (0.5%)

2 (0.4%)

1 (0.2%)

6 (0.7%)

Stratified by indication

Melanoma

NSCLC

HNSCC

CRC

HL

UC

 Assessable patients^a

1465

1236

101

54

220

579

 Inconclusive patients^b

1063

445

39

0

38

70

 Evaluable patients^c

402

791

62

54

182

509

  Negative^d

395 (98.3%)

762 (96.3%)

59 (95.2%)

51 (94.4%)

179 (98.4%)

497 (97.6%)

  Non–treatment emergent positive^d

4 (1.0%)

6 (0.8%)

2 (3.2%)

2 (3.7%)

2 (1.1%)

5 (1.0%)

   Neutralizing negative

3 (0.7%)

5 (0.6%)

2 (3.2%)

2 (3.7%)

2 (1.1%)

5 (1.0%)

   Neutralizing positive

1 (0.2%)

1 (0.1%)

  Treatment emergent positive^d

3 (0.7%)

23 (2.9%)

1 (1.6%)

1 (1.9%)

1 (0.6%)

7 (1.4%)

   Neutralizing negative

2 (0.5%)

18 (2.3%)

1 (1.6%)

1 (1.9%)

5 (1.0%)

   Neutralizing positive

1 (0.2%)

5 (0.6%)

0

0

1 (0.6%)

2 (0.4%)